E.L.J. Hoogervorst

1.5k total citations
32 papers, 1.0k citations indexed

About

E.L.J. Hoogervorst is a scholar working on Pathology and Forensic Medicine, Hematology and Economics and Econometrics. According to data from OpenAlex, E.L.J. Hoogervorst has authored 32 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Pathology and Forensic Medicine, 6 papers in Hematology and 6 papers in Economics and Econometrics. Recurrent topics in E.L.J. Hoogervorst's work include Multiple Sclerosis Research Studies (25 papers), Autoimmune and Inflammatory Disorders Research (6 papers) and Health Systems, Economic Evaluations, Quality of Life (6 papers). E.L.J. Hoogervorst is often cited by papers focused on Multiple Sclerosis Research Studies (25 papers), Autoimmune and Inflammatory Disorders Research (6 papers) and Health Systems, Economic Evaluations, Quality of Life (6 papers). E.L.J. Hoogervorst collaborates with scholars based in Netherlands, United States and Germany. E.L.J. Hoogervorst's co-authors include Chris H. Polman, Bernard M.J. Uitdehaag, Nynke F. Kalkers, Joep Killestein, Charlotte E. Teunissen, CH Polman, A. C. Van Loenen, Frederik Barkhof, Marcus Reif and Jack Zwemmer and has published in prestigious journals such as SHILAP Revista de lepidopterología, Neurology and International Journal of Molecular Sciences.

In The Last Decade

E.L.J. Hoogervorst

32 papers receiving 1000 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
E.L.J. Hoogervorst Netherlands 20 675 195 164 164 140 32 1.0k
Nastaran Majdinasab Iran 21 515 0.8× 150 0.8× 78 0.5× 272 1.7× 53 0.4× 84 1.0k
Virender Bhan Canada 19 1.1k 1.7× 374 1.9× 259 1.6× 252 1.5× 39 0.3× 40 1.6k
Fereshteh Ashtari Iran 17 634 0.9× 209 1.1× 121 0.7× 203 1.2× 26 0.2× 82 952
Marco Frontoni Italy 15 400 0.6× 300 1.5× 99 0.6× 102 0.6× 42 0.3× 34 933
Lorena Lorefice Italy 23 956 1.4× 250 1.3× 217 1.3× 183 1.1× 28 0.2× 102 1.5k
Nadia Reider Canada 10 921 1.4× 242 1.2× 182 1.1× 182 1.1× 17 0.1× 11 1.2k
T. Henze Germany 17 469 0.7× 476 2.4× 55 0.3× 136 0.8× 204 1.5× 67 1.2k
O.R. Hommes Netherlands 17 571 0.8× 287 1.5× 327 2.0× 260 1.6× 52 0.4× 53 1.3k
Bruno Musch United States 12 782 1.2× 615 3.2× 171 1.0× 99 0.6× 40 0.3× 29 1.4k
Elisabeth Pedersen Norway 9 271 0.4× 117 0.6× 143 0.9× 129 0.8× 36 0.3× 19 723

Countries citing papers authored by E.L.J. Hoogervorst

Since Specialization
Citations

This map shows the geographic impact of E.L.J. Hoogervorst's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E.L.J. Hoogervorst with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E.L.J. Hoogervorst more than expected).

Fields of papers citing papers by E.L.J. Hoogervorst

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by E.L.J. Hoogervorst. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E.L.J. Hoogervorst. The network helps show where E.L.J. Hoogervorst may publish in the future.

Co-authorship network of co-authors of E.L.J. Hoogervorst

This figure shows the co-authorship network connecting the top 25 collaborators of E.L.J. Hoogervorst. A scholar is included among the top collaborators of E.L.J. Hoogervorst based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with E.L.J. Hoogervorst. E.L.J. Hoogervorst is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Heerings, Marco, Marina Hakobjan, Ward De Witte, et al.. (2022). Whole Exome Sequencing in Multi-Incident Families Identifies Novel Candidate Genes for Multiple Sclerosis. International Journal of Molecular Sciences. 23(19). 11461–11461. 5 indexed citations
2.
Kempen, Zoé L. E. van, E.L.J. Hoogervorst, Eva Strijbis, et al.. (2021). Varicella zoster-associated acute retinal necrosis and central nervous system complications in natalizumab treated MS patients. Multiple Sclerosis and Related Disorders. 50. 102838–102838. 7 indexed citations
3.
Jongen, Peter Joseph, et al.. (2021). Patient decision aid based on multi-criteria decision analysis for disease-modifying drugs for multiple sclerosis: prototype development. BMC Medical Informatics and Decision Making. 21(1). 123–123. 7 indexed citations
4.
Kempen, Zoé L. E. van, E.L.J. Hoogervorst, Mike P. Wattjes, et al.. (2020). Personalized extended interval dosing of natalizumab in MS. Neurology. 95(6). e745–e754. 35 indexed citations
5.
Smits, Lisa M., et al.. (2020). A tumefactive demyelinating lesion in a person with MS after five years of fingolimod. Multiple Sclerosis and Related Disorders. 40. 101978–101978. 6 indexed citations
6.
Jongen, Peter Joseph, W.A.J.G. Lemmens, E.L.J. Hoogervorst, & Rogier Donders. (2017). Glatiramer acetate treatment persistence - but not adherence - in multiple sclerosis patients is predicted by health-related quality of life and self-efficacy: a prospective web-based patient-centred study (CAIR study). Health and Quality of Life Outcomes. 15(1). 50–50. 9 indexed citations
7.
Killestein, Joep, Cyra E Leurs, E.L.J. Hoogervorst, et al.. (2017). Five cases of malignant melanoma during fingolimod treatment in Dutch patients with MS. Neurology. 89(9). 970–972. 20 indexed citations
8.
Jongen, Peter Joseph, W.A.J.G. Lemmens, Raymond Hupperts, et al.. (2016). Persistence and adherence in multiple sclerosis patients starting glatiramer acetate treatment: assessment of relationship with care received from multiple disciplines. Patient Preference and Adherence. 10. 909–909. 10 indexed citations
9.
Jongen, Peter Joseph, E.L.J. Hoogervorst, Erik van Munster, et al.. (2016). Patient-reported adverse effects of high-dose intravenous methylprednisolone treatment: a prospective web-based multi-center study in multiple sclerosis patients with a relapse. Journal of Neurology. 263(8). 1641–1651. 30 indexed citations
10.
Heine, Martin, et al.. (2014). Validity of Maximal Exercise Testing in People With Multiple Sclerosis and Low to Moderate Levels of Disability. Physical Therapy. 94(8). 1168–1175. 30 indexed citations
11.
Gool, Arthur R. Van, E.L.J. Hoogervorst, Lex Wunderink, & C.L. Mulder. (2014). [Contribution to quality of care or caught in a digital labyrinth? Experience with electronic records of patients receiving long-term mental health care].. PubMed. 56(6). 394–401. 1 indexed citations
12.
13.
Flier, Wiesje M. van der, et al.. (2008). Associations between Patterns of EEG Abnormalities and Diagnosis in a Large Memory Clinic Cohort. Dementia and Geriatric Cognitive Disorders. 27(1). 18–23. 48 indexed citations
14.
Jonge, Peter de, E.L.J. Hoogervorst, Frits J. Huyse, & Chris H. Polman. (2004). INTERMED: a measure of biopsychosocial case complexity: one year stability in Multiple Sclerosis patients. General Hospital Psychiatry. 26(2). 147–152. 25 indexed citations
15.
Teunissen, Charlotte E., C Dijkstra, Chris H. Polman, et al.. (2003). Decreased levels of the brain specific 24S-hydroxycholesterol and cholesterol precursors in serum of multiple sclerosis patients. Neuroscience Letters. 347(3). 159–162. 85 indexed citations
16.
Hoogervorst, E.L.J.. (2003). One year changes in disability in multiple sclerosis: neurological examination compared with patient self report. Journal of Neurology Neurosurgery & Psychiatry. 74(4). 439–442. 35 indexed citations
17.
Hoogervorst, E.L.J., Chris H. Polman, & Frederik Barkhof. (2002). Cerebral volume changes in multiple sclerosis patients treated with high-dose intravenous methylprednisolone. Multiple Sclerosis Journal. 8(5). 415–419. 42 indexed citations
18.
Hoogervorst, E.L.J., Nynke F. Kalkers, Bernard M.J. Uitdehaag, & Chris H. Polman. (2002). A Study Validating Changes in the Multiple Sclerosis Functional Composite. Archives of Neurology. 59(1). 113–113. 35 indexed citations
19.
Hoogervorst, E.L.J.. (2002). The INTERMED: a screening instrument to identify multiple sclerosis patients in need of multidisciplinary treatment. Journal of Neurology Neurosurgery & Psychiatry. 74(1). 20–24. 29 indexed citations
20.
Hoogervorst, E.L.J., et al.. (2001). Differential treatment effect on measures of neurologic exam, functional impairment and patient self-report in multiple sclerosis. Multiple Sclerosis Journal. 7(5). 335–339. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Nastaran Majdinasab Breakdown of academic impact, for papers by Virender Bhan Breakdown of academic impact, for papers by Fereshteh Ashtari Breakdown of academic impact, for papers by Marco Frontoni Breakdown of academic impact, for papers by Lorena Lorefice Breakdown of academic impact, for papers by Nadia Reider Breakdown of academic impact, for papers by T. Henze Breakdown of academic impact, for papers by O.R. Hommes Breakdown of academic impact, for papers by Bruno Musch Breakdown of academic impact, for papers by Elisabeth Pedersen
Rankless by CCL
2026